Inc. (CRM) Falls 2.51% for January 28

Equities Staff  |

One of the S&P 500’s big losers for Thursday January 28 was Inc. (CRM). The company’s stock fell 2.51% to $65.74 on volume of 6.61 million shares.

The stock opened the day at 66.88 and traded between a low of $65.27 and a high of $67.50. The stock finished the day down $1.695 per share. Inc. has an average daily volume of 3.83 million and a total float of 664 million shares. The 50-day SMA for Inc. is $76.74 and its 200-day SMA is $73.56. The high for the stock over the last 52 weeks is $82.90 and the low is $55.45. Inc provides enterprise cloud computing solutions, offering social and mobile cloud apps and platform services, as well as professional services to facilitate the adoption of its solutions. Inc. is centered in San Francisco, CA, and has 16,000 employees. Today’s trading day leaves the company with a market cap of $43.65 billion. The company has a P/S ratio of n/a, P/B ratio of 11.28, and a n/a.

For a complete fundamental analysis analysis of Inc., check out’s Stock Valuation Analysis report for CRM. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Global Cannabis

Global Cannabis Applications Corp is engaged in the design, acquire data and develop applications for smartphones and tablets. The company offer Citizen Green platform, an end to end infrastructure to…